AtriCure, Inc.
ATRC
Positions held
Your positionsATRC isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- AtriCure is positioned in a growing healthcare market, focusing on innovative medical instruments that address significant patient needs, which can enhance its competitive edge.
- Revenue increased by 9% from the prior quarter, reaching $154 million.
- Operating margin expanded to 6.3%, indicating improved operational efficiency.
- Despite growth, AtriCure's trailing P/E ratio of 255.62 suggests that the stock may be overvalued compared to its earnings.
- The company reported a net income loss of $30.438 million in 2023, highlighting ongoing profitability challenges.
- The operating margin for 2025 was negative at -1.77%, reflecting difficulties in maintaining profitability.
Fundamentals
| Market cap | $2.69B | Enterprise value | $2.59B | Trailing P/E | 251.62 | Forward P/E | 121.76 |
| PEG | 10.00 | Price / book | 5.20 | Beta | 1.25 | Dividend yield | 0.00% |
| Revenue growth | 12.8% | Earnings growth | — | Gross margin | 76.3% | Operating margin | 6.3% |
| Profit margin | 1.9% | ROE | 2.2% | ROA | 1.3% | Debt / equity | 0.14 |
| Current ratio | 4.22 | Free cash flow | $48.81M | Analyst recommendation | buy | Mean target | $54.89 |
| 52w high | $61.70 | 52w low | $25.36 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $154M | $141M | $141M | $134M | $136M | — |
| Op margin | 6.3% | 0.4% | 1.8% | 0.2% | -4.5% | — |
| Net income | $9.0M | $0.1M | $1.8M | -$0.3M | -$6.2M | — |
| Gross margin | 77.2% | 77.4% | 75.0% | 75.5% | 74.5% | — |
| Gross profit | $119M | $109M | $105M | $101M | $101M | — |
| Operating income | $9.7M | $0.5M | $2.5M | $0.2M | -$6.2M | — |
- Revenue +9% vs prior quarter ($154M vs $141M).
- Gross margin 77.2% (was 77.4% prior quarter).
- Operating margin expanded to 6.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $535M | $465M | $399M | $330M | — |
| Op margin | -1.8% | -8.6% | -6.7% | -12.9% | — |
| Net income | -$11.4M | -$44.7M | -$30.4M | -$46.5M | — |
| Gross margin | 75.0% | 74.7% | 75.2% | 74.4% | — |
| Gross profit | $401M | $348M | $300M | $246M | — |
| Operating income | -$9.4M | -$40.0M | -$26.7M | -$42.7M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · AtriCure (ATRC) Stock Gets Fair Value Bump As Analysts Weigh Procedure Growth And Risks
2026-09-25 · AtriCure (ATRC) Stock Looks Rich Against Its Sales Base
2026-09-25 · Why AtriCure (ATRC) Is Back In The Spotlight
2026-09-24 · Atricure Insider Sold Shares Worth $271,140, According to a Recent SEC Filing
2026-09-21 · AXT Inc. (AXTI) Climbs 16% on S&P 600 Addition
2026-09-14 · Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?
2026-09-13 · AtriCure CTO Sells 3,657 Shares
2026-09-10 · Do Options Traders Know Something About AtriCure Stock We Don't?
2026-09-09 · AtriCure, Inc. (ATRC) Hit a 52 Week High, Can the Run Continue?
2026-09-04 · Atricure Insider Sold Shares Worth $407,558, According to a Recent SEC Filing
2026-09-02 · Needham Raises Price Target on AtriCure to $64 From $45, Keeps Buy Rating
Price (daily)
Full chart · RSI · MACD · patterns